PATENT CLAIM ANALYSIS

Application Number: 15888350
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.

Claim (Index 32):
The method of  claim 28 , wherein the composition causes an increase in fetal hemoglobin mRNA or protein expression.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 88.0
- Lexical Diversity: 1.09677
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13063524', '13743399', '14647547', '15816083', '13992669']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8418420088961268
- 35 USC 102 Novelty (BERT): 0.6592599302894826
- Combined Prediction Score: 0.8235838010354625
- Mean Citation Score: 635.224112
- Max Citation Score: 823.47217
- Similarity Product: 583.5709227583267

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test